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Abstract
Parkinson’s disease (PD) coincides with a dramatic loss of dopaminergic neurons within the substan-
tia nigra. A key player in the loss of dopaminergic neurons is oxidative stress. Dopamine (DA)
metabolism itself is strongly linked to oxidative stress as its degradation generates reactive oxygen
species (ROS) and DA oxidation can lead to endogenous neurotoxins whereas some DA derivatives
show antioxidative effects. Therefore, DA metabolism is of special importance for neuronal redox-
homeostasis and viability.
In this review we highlight different aspects of dopamine metabolism in the context of PD and neu-
rodegeneration. Since most reviews focus only on single aspects of the DA system, we will give a
broader overview by looking at DA biosynthesis, sequestration, degradation and oxidation chemistry
at the metabolic level, as well as at the transcriptional, translational and posttranslational regulation
of all enzymes involved. This is followed by a short overview of cellular models currently used in
PD research. Finally, we will address the topic from a medical point of view which directly aims to
encounter PD.
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Introduction
The age-related Parkinson’s disease (PD) is the most common neurodegenerative motor disorder in the
world, affecting millions of elderly people. The motor symptoms of PD, such as rigidity, tremor or
bradykinesia, are caused by the degeneration of dopaminergic neurons within the substantia nigra pars
compacta. Despite intensive research over the past years, there is no cure for this disease and even
diagnosis of PD is complicated due to a lack of reliable diagnostic tests.
There are sporadic and inheritable forms of PD. Sporadic PD is by far the most common, and thus rep-
resents the more pressing medical need. However, similarities in both forms have led to the assumption
that there are common underlying molecular mechanisms [1,2].
Major causes of neurodegeneration are mitochondrial impairment and oxidative stress. In this context
it is interesting to note that although the adult human brain constitutes only about 2% of body weight,
it consumes about 20% of the body’s oxygen and glucose for the production of energy in the form of
adenosine triphosphate (ATP) [3]. Thus, this organ is particularly exposed to the consequences of mito-
chondrial energy metabolism malfunction and its resulting injurious transition. In addition to these well
known parameters, the catecholamine (CA) metabolism is a unique feature of catecholaminergic neu-
rons and represents an additional source for reactive oxygen species (ROS) production. According to this
prompted oxidative stress, brain tissue samples of post mortem PD patients comprise increased levels
of lipid peroxidation in the substantia nigra [4]. Catecholamine metabolism might be especially crucial
for cellular redox homeostasis and could be a trigger for ROS overload, i.e. ROS that can no longer
be detoxified by the cell. To better understand the catecholamine metabolism and its consequences to
cellular integrity, a systems approach on a metabolic level would be beneficial.
Systems biology and personalized medicine have become a fast growing field and have been more and
more advanced especially in the light of high computing power, low cost sequencing opportunities and
complex networks, underlying disease pathologies. Cellular regulation typically operates on four lev-
els, besides regulation of genome, transcriptome and proteome the metabolome is the fourth level of
regulation. Altered metabolic levels have in turn impact on the level of genome, transcriptome and pro-
teome. Analyzing the metabolome means to make a metabolic snapshot of the cell, which is challenging
because metabolism has turnover rates in the range of seconds.
Recent publications, that have been made possible by the advancement of new technologies, describe
in detail the underlying molecular mechanisms favoring these metabolic changes. In terms of today’s
research these advancements pushed our limits and opened new horizons. Key technologies are very
sensitive mass spectrometers coupled to gas or liquid chromatography and stable isotope labeling [5,6].
The simultaneous measurement of several hundred metabolites in one single sample is no longer a
challenge [7]. However, the key advancement in all large scale and “omics” analyses is the valuable
readout of these large data sets, from their respective software packages [8]. In terms of metabolomics,
this means identifying significantly deregulated metabolites, calculating enzyme activities, tracing the
metabolic fate of single metabolites and to even identify unknown metabolites. These advancements
can be observed in the field of cancer research, which has evolved tremendously over the last years [9].
Different examples nicely demonstrate the adaptation of cellular metabolism as an result of genetic
reorganization and the impact of metabolism on cellular and systemic functionality [10,11].
Mining the literature of the last decade and looking for data related to DAmetabolism or CAmetabolism
in general – also with respect to PD – we felt that this area of research is underrated, at least in the field of
metabolism. Most research has been based on genetic studies, since several genes could be successfully
linked to a PD phenotype. But we should not forget that most cases of PD are still idiopathic, rather than
of genetic heritage. Therefore, additional causes for the loss of dopaminergic (DAergic) neurons over
time, should exist. One key player for DAergic cell death might be the DA metabolism itself, which
serves as a major source of intracellular ROS production. In this review we present a detailed overview
over DA metabolism in the central nervous system, integrating molecular and biochemical aspects. We
will refer to informative articles that go deeper into the individual topics.
On the origin of dopamine research
DA was first prepared long before its importance as neurotransmitter was discovered. It was originally
synthesized in 1910 because of the strong physiological effects, observed for other phenolic bases like
epinephrine [12,13], but due to its comparatively low effect on arterial blood-pressure it was mostly
overlooked. The first time DA was found to occur in an organism was as a pigment-building metabolite
in the plant Sarothamnus scoparius [14]. Later on, it was found to be a substrate of aromatic amino acid
decarboxylase (AADC) [15]; which could be isolated from sympathetic ganglia [16] and other animal
tissues [17]. DA is also prevalent in invertebrates [18].
Initially DA was only assumed to be a precursor of the catecholic neurotransmitters epinephrine (E)
and norepinephrine (NE) or considered to be an intermediate in tyrosine degradation [15]. It was only
later that DA was recognized as an independent neurotransmitter [19,20]. It took some more time
till the first DA receptor was discovered [21]. The Nobel Prize in medicine and physiology in 2000
was awarded to Arvid Carlsson together with Eric Kandel and Paul Greengard, for their research in
the field of CAergic neurotransmission in the 1950s that lead to new techniques for DA measurement,
and most importantly to the insight that DA was itself a neurotransmitter [22]. Quickly afterwards
PD was associated with neostriatal DA depletion [23] which led to the first PD treatment with L-3,4-
dihydroxyphenylalanine (DOPA, levodopa) [24] which is still used today. Other disorders have in the
meanwhile been associated with DA metabolism or signalling, emphasizing the importance of a well
balanced DA metabolism. In schizophrenic patients increased DA release is observed [25] and PD-like
side effects can occur in schizophrenia treatment [26]. Deficient DA-signalling also plays a role in
attention deficit hyperactivity disorder (ADHD) [27] and GTP cyclohydrolase 1 deficiency (see GTPCH
section) which leads to another movement disorder named Segawa disease [28].
Dopamine biosynthesis
Although DA is an important neurotransmitter in the brain, a substantial part of the overall DA in the
body is produced outside the brain by mesenteric organs [29]. We will focus here on DA production
within the central nervous system (CNS). The classical pathway for DA biosynthesis was already postu-
lated by Blaschko in 1939 [30]. The two-step biosynthesis of DA takes place in the cytosol of CAergic
neurons and starts with the hydroxylation of L-tyrosine at the phenol ring by tyrosine hydroxylase (TH)
to yield DOPA (Figures 1, 2). This oxidation is strongly regulated and depends on tetrahydrobiopterin
(BH4) as a cofactor which is synthesized from guanosine triphosphate (GTP) by GTP cyclohydrolase
(GTPCH). DOPA is then decarboxylated to DA by aromatic amino acid decarboxylase (AADC, also
known as DOPA decarboxylase).
Figure 1 Neuronal DA metabolism. In the neurite of DAergic neurons, DA is synthesized by com-
bined action of TH and AADC and imported into synaptic vesicles by VMAT2. DA leaking from the
vesicles is deaminated by MAO. Upon neuronal excitation DA is released into the synaptic cleft for sig-
nal transduction. DA signaling stops by reimport to the presynaptic neuron and recycling or by import to
surrounding cells and degradation by COMT, MAO, AR, ADH and ALDH. The main DA degradation
products are DOPAC and HVA. In cytoplasmic vesicles NM is built of DA oxidation products and other
components and can chelate iron. DA or DOPA can be oxidized to their corresponding reactive quinones
(Q) that react further on to form a variety of partly neurotoxic compounds and protein adducts. These
toxins and the ROS generated from DA deamination can cause cell damage and neurodegeneration. See
text and Figures 2, 4 and 5 for further details and references.
Figure 2 DA biosynthesis and degradation. The major pathway for DA biosynthesis starts at tyrosine
or phenylalanine which can be hydroxylated by phenylalanine hydroxylase. Tyrosine is hydroxylated to
form DOPA, now bearing the catechol moiety, by BH4-dependent tyrosine hydroxylase or alternatively
by tyrosinase. Decarboxylation of DOPA by AADC leads then to DA. In another pathway for DA syn-
thesis AADC action occurs before the hydroxylation at the aromatic ring. Tyramine is then oxidized
by Cyp2D. Besides being a neurotransmitter itself, DA is also the precursor of epinephrine and nore-
pinephrine. DA degradation is performed by COMT,MAO, ADH, ALDH and AR in variable order lead-
ing to DOPAC and HVA as the main endproducts. Phenolsulfotransferases and uridine diphosphoglu-
curonosyltransferases catalyze conjugation reactions with phosphate and glucuronic acid respectively.
The relative contributions of the different enzymes are strongly species-, tissue- and celltype-dependent.
The depicted reactions may occur in distinct compartments.
Besides this classical biosynthetic pathway, a cytochrome P450-mediated pathway was shown to exist
in rat in vivo [31,32]. In this pathway decarboxylation precedes hydroxylation thus tyrosine is decar-
boxylated to tyramine which can then be hydroxylated by Cyp2D proteins (Figures 1, 2). Although the
contribution to total DA synthesis seems to be low, it might become important under specific condi-
tions [32].
Another possibility for DA biosynthesis is the tyrosinase catalyzed tyrosine hydroxylation and the sub-
sequent DOPA uptake by CAergic neurons. Tyrosinase is normally involved in the biosynthesis of
peripheral eumelanins and phaeomelanins [33], but for TH-negative mice this is the major source of
CAs. Yet tyrosinase-lacking albino TH-negative mice still seem to have some source of CA [34]. It is
not clear if this remaining DA is produced via the Cyp2D pathway or if other mechanisms still have to
be discovered.
In CAergic neurons DA is readily sequestered into synaptic vesicles by secondary active transport via
the vesicular monoamine transporter 2 (VMAT2) [35] (Figure 1). Inside these vesicles oxidation-prone
DA is stabilized by the slightly acidic pH there [36]. This prevents oxidative stress in the cytosol [37].
Oxidative stress is further minimized by association of DA biosynthetic enzymes TH and AADC with
VMAT2 [38]. Vesicular sequestration by VMAT2 can be irreversibly inhibited by the drug reserpine.
Amphetamine and similar compounds inhibit VMAT2 directly and further collapse the proton gradient
necessary for DA transport [35,39] (Figure 1).
To control DA homeostasis, the enzymes involved in DA synthesis – TH, GTPCH and AADC – play
an important role to prevent excessive oxidative stress. In the following paragraphs we will present the
underlying regulatory mechanisms that control enzyme activity of these proteins.
Tyrosine hydroxylase
TH catalyzes the first step of DA biosynthesis and is strongly regulated. It constitutes, together with
tryptophane hydroxylase and phenylalanine hydroxylase, the pterin-dependent aromatic amino acid
monooxygenases [40,41]. TH consists of four identical subunits, each catalytically active and each
of them requiring BH4, ferrous ion and O2 to oxidize tyrosine to DOPA [42].
Excellent in-depth reports of TH are available and should be consulted for further information [43,44].
Here we summarize the most important information to understand the regulation of TH activity and its
importance for DA synthesis.
TH is always coded by one single gene [45]. However, humans possess four TH isoforms due to alterna-
tive splicing in exon 2 [45-48] (Figure 3). Other primates have two isoforms and non-primate mammals
have only one TH isoform [49,50]. Human TH1 (hTH1) is most similar to rat TH and hTH1 and hTH2
are predominantly expressed in human brain [47]. One should note, that the websites ensemble.org and
NCBI show a different order and do not include TH2. In this manuscript we decided to stick to the
nomenclature used in the literature (Figure 3).
Figure 3 Overview of TH isoforms. A) Overview of the four human TH isoforms with their respective
amino acid length. Asterisks indicate the position of the serines that are targeted by phosphorylation.
Numbers on the bottom indicate amino acids located after a splice section. B) Alignment of TH1
and TH4 for illustration of the additional amino acids, present in the different isoforms. The numbers
correspond to the nucleotide numbering.
The structure of all four isoforms is based on the same principle: one N-terminal regulatory domain
(150AA), a central catalytic domain (300AA) and the C-terminal part, coding for a leucine zipper
domain which is responsible for tetramer formation [51]. Loss of tetramer formation ability leads to a
70% drop of TH activity [52].
Regulation of TH
TH is regulated on transcriptional [44,53-57] and post-transcriptional level [53] by covalent modifica-
tions, protein-protein-interaction and by allosteric regulation [43].
Synthesized CAs compete with the TH cofactor BH4 to bind the ferric ion at the catalytic site of TH [42,
58-60]. Thus, high CA levels inhibit TH activity and thereby regulate its own intracellular concentrations
via feedback regulation. The regulatory domain of hTH is targeted by phosphorylation at serine 19, 31
and 40 by various kinases, such as PKA, PKC CaMPKII, PKG, MPK, ERK which results in increased
stability and/or activity [44]. Rat TH can also be phosphorylated at serine 8, but hTH has a threonine
on this position instead. In vivo, depolarized cells increase their intracellular calcium concentrations via
voltage sensitive calcium channels. Increase of calcium leads to the activation of different kinases, that
in turn phosphorylate different serines on TH. Due to phosphorylation, the regulatory domain of TH
undergoes a conformational change and dissociation of bound CA is facilitated. The phosphorylated
version shows a sixfold higher dissociation rate compared to the non-phosphorylated form [59]. This is
also demonstrated by Daubner et al. who generated phosphomimetic versions of TH by replacing Ser 40
by glutamate [60]. This version shows lowered inhibition by DA.
Phosphorylation of Ser 40 seems to have the strongest effect in terms of TH activation. Depending on the
kinase and the position where TH is phosphorylated, the activity can increase up to 10 fold [60]. On the
contrary, phosphorylation of Ser 19 seems to have two other purposes: a) it favors binding of regulatory
14–3-3 protein which in turn stabilizes TH [61-63] b) it facilitates Ser 40 phosphorylation (hierarchical
phosphorylation) [64-66]. Phosphorylated Ser 31 results in a lowered Km value for BH4 binding and a
slight increase in activity, but this increase is only minor compared to Ser 40 phosphorylation [44]. Since
Ser 40 seems to be the most important phosphorylation target in respect of activation it is interesting to
note that only 5–11% of total TH proteins are phosphorylated in vivo [44,64,67].
To inactivate TH, there exist phosphatases (PP2A and PP2C) that can reverse the phosphorylation and
might, therefore, function as deactivators [68-70]. TH can be inactivated by nitration, for example via
reactive nitrogen species (peroxynitrite) or via S-thiolation on cysteine residues [71-74]. Regarding the
stability of this enzyme, dephosphorylated TH versions are more stable compared to their phospho-
rylated counterparts. The explanation for this might be pretty simple, because DA levels have to be
maintained at very defined levels and must not exceed thresholds of toxicity. Higher turnover rates of
the active enzyme seem to be more feasible in order to better control how much DOPA is produced.
Besides serine 19, 31 and 40, arginine 37 and 38 have regulatory relevance for TH. Engineered en-
zymes with a deletion up to amino acid 39 [75] or arginine 37 and 38 replaced by glycine or glutamate
showed higher activity due to favored BH4 affinity [76-78]. The authors speculated that these two amino
acids might have important functions for the tertiary structure of the regulatory domain and enable DA
mediated inhibition of TH [43].
A PEST domain has also been proposed for TH [79] and ubiquitylation of TH and associated protea-
somal degradation was demonstrated [80,81]. However, we could not find any reference stating which
lysine is targeted by ubiquitylation. UbPred an ubiquitylation site prediction tool [82] identified Lys 78
as the most likely target in TH4 (528AA). This would make sense as it lies within the regulatory N-
terminal domain, which is exposed to the outside of the protein and would, therefore, be accessible for
E3 ubiquitin ligase.
In addition to covalent modifications, TH stability is also controlled by interaction with other proteins
(14–3-3, DJ-1, -synuclein, VMAT-2, AADC, GTPCH) via the N-terminus of TH [38,43,61,62,83-
85]; see also BH4 and GTPCH section. These interactions affect TH stability, activity and probably
intracellular localization, which finally affects DA production.
One additional important factor regarding DA production and stability seems to be the intracellular
O2 concentration. The O2 concentration in brain tissue is normally at 1–5%, whereas atmospheric
oxygen levels are around 20%. Firstly, increased oxygen levels induce DA oxidation thus triggering the
generation of ROS and secondly, the oxygen level influences TH protein abundance and activity [86,87].
It is important to mention that most biochemical in vitro studies have been performed with rat or other
non-human TH. However, one should keep in mind that there are substantial differences between the
species’ TH activities and their CA metabolism [60,88,89]. In summary, it is the N-terminal part of TH
and especially its state of modification that plays an important role in protein stability and activity. In
addition to active regulation of TH, the protein depends on the cofactor BH4 for catalysis. Regulation
of BH4 synthesis and the role of GTPCH for DA production will be explained in the following section.
BH4 and GTPCH
6R-L-erythro-5,6,7,8-tetrahydrobiopterine (BH4) functions as a cofactor for the pterin-dependent aro-
matic amino acid monooxygenases and for NO synthase. BH4 can directly react with molecular oxygen
to facilitate hydroxylation of the substrate. It is synthesized in three steps from GTP [90] (for review
see Thöny et al. [91] and Werner et al. [92]). As an alternative to de novo synthesis of BH4, the cofac-
tor can also be recycled via pterin-4a-carbinolamine dehydratase (PCD) and dihydropteridine reductase
(DHPR) [91] (Figure 4). On the other hand, too high BH4 levels inhibit TH and are even toxic to the
cell by inhibiting complex I and IV of the electron transport chain [93].
Figure 4 Regulation of DA synthesis in dependency on BH4. Dopamin synthesis relies on hy-
droxylation of phenylalanine, hydroxylation of tyrosine and decarboxylation of DOPA (blue box). The
key enzyme tyrosine hydroxylase (TH) needs tetrahydrobiopterine (BH4) as a cofactor to catalyze the
hydroxylation of tyrosine. Guanosine triphosphate (GTP) is the precursor for BH4 synthesis and GTP
cyclohydrolase I is the key enzyme in this reaction (grey box). GTP cyclohydrolase I converts GTP into
7,8-dihydroneopterine triphosphate which is subsequently converted into 6-pyruvoyltetrahydropterine
by PTPS. SR finally converts 6-pyruvoyltetrahydropterine into BH4. GTPCH is stimulated by Pheny-
lalanine and repressed by high BH4 levels. in this case BH4 binds to the GTPCH feedback regulatory
protein (GFRP). BH4 can be recycled via pterin-4a-carbinolamine dehydratase (PCD) and dihydropteri-
dine reductase (DHPR) to maintain sufficient BH4 (yellow box).
The first and rate-limiting reaction in BH4 production is catalyzed by the enzyme GTP cyclohydrolase I
(GTPCH). GTPCH is coded by one gene and is built of six exons [94]. Alternative splicing yields at least
three different splice variants, but only one version seems to be catalytically active. In addition, GTPCH
is expressed in a tissue specific manner with especially high mRNA concentrations within serotonergic
neurons. Results about GTPCH in CA producing neurons are controversial [95-98]. Dassesse et al.
found relatively strong GTPCH immunoreactivity in the substantia nigra of rat brain [98]. Dominant
as well as autosomal recessive GTPCH mutations have been reported and linked to DOPA responsive
dystonia [99-102]. Other diseases associated with GTPCH or BH4 deficiency, respectively are hyper-
phenylalaninemia, cardiovascular disorders and phenylketonuria (PKU) [91,92,103,104].
Expression of GTPCH is regulated on transcriptional and post-transcriptional level. Administration of
cAMP results in up-regulation of GTPCH gene expression. GTPCH activity is induced by phenylalanine
and inhibited by BH4 via the GTPCH feedback regulatory protein (GFRP) [91,97,105,106]. In addition,
phosphorylation of Ser 81 increases GTPCH activity [107-109].
GTPCH-TH-interaction
Bowling et al. [83] could demonstrate that TH interacts with GTPCH and that this interaction depends
on the phosphorylation of both. Interaction with TH prevented BH4-mediated inhibition of GTPCH,
resulting in increased GTPCH and TH activities. These findings suggest that GTPCH activity is stimu-
lated as long as TH is present in a phosphorylated (thus itself active) state and therefore DA production
is also dependent on GTPCH. Experiments in Drosophila melanogaster showed that administration of
BH4 could not restore TH activity in flies with mutated GTPCH versions. The authors assume that full
TH activity depends on the interaction of TH with GTPCH [110]. These results were also confirmed by
Bowling et al. [83], who showed that addition of GTPCH to TH increased Vmax of TH. Interestingly,
they also found a functional explanation for the phenomenon that high BH4 concentrations inhibit TH
activity as previously reported [47] and that only physiological concentrations of 25–100 M increased
TH activity. Others report that concentrations of 10 M have activating effects on TH [68]. However,
there is a common agreement that the BH4 level has to be balanced. The concept is, that only a certain
concentration of BH4 molecules results in active TH, because too high concentrations block GTPCH on
the N-terminal part and prevent thereby the interaction with TH. Too low concentrations will be limit-
ing due to lacking cofactor molecules for TH. In summary, TH needs both, the cofactor BH4 and the
interaction partner GTPCH for functionality.
Although TH interaction with GTPCH prevents feedback regulation of GTPCH by its end product BH4,
TH can still be inhibited by DA, even in the presence of GTPCH. This is based on the way these two
enzymes undergo complex formation and the resulting three-dimensional structure [83]. These findings
further advocate the complex underlying regulatory mechanisms that control intracellular DA levels.
Aromatic amino acid decarboxylase
AADC was probably first described by Blaschko [30] and subsequently described by Schales and
Schales [111] and Clark et al. [112]. Blaschko already asked the question whether AADC is specific to
DOPA or if it can use other aromatic amino acids as substrate. Today we know that AADC uses pyri-
doxal phosphate (vitamin B6) as cofactor [113] and catalyzes the decarboxylation of several aromatic
L-amino acids such as L-DOPA, L-tyrosine, L-tryptophane and L-histidine, thus being an important
enzyme in the synthesis of different neurotransmitters and not exclusively specific to DOPA.
How CA biosynthesis in the human brain is regulated on the level of AADC is not completely clear
[114]. AADC is regulated at transcriptional level and at post-translational level [115-117]. At tran-
scriptional level AADC can be differentially expressed by alternative promoter usage and by alternative
splicing [118]. At protein level AADC is regulated by phosphorylation [119] and DA receptor stimu-
lation [117,120,121]. Based on the two different regulation types: transcriptional and post-translational
regulation, AADC is regulated by a quick acting, short-term mechanism, via regulation of the protein
activity and in a slower longer lasting regulation, by adapting the gene expression [115,116].
AADC activity is dependent on DA levels. By using the DA receptor antagonist cis-flupenthixol and
haloperidol, an increase of striatal AADC activity could be detected [122,123]. DA receptor antagonists
enhance the activity of AADC, whereas agonists are more likely to reduce activity [117,123]. In ac-
cordance to this, inhibition of MAO decreases AADC activity, implying that higher DA levels result in
more DA bound to DA receptors [120,124]. Depletion of DA by reserpine treatment results in AADC
activation [121]. Similar as TH, AADC is regulated in a species and tissue specific manner [115,116],
which is even more reasonable for AADC, since it catalyzes the decarboxylation of different substrates
in a wide range of tissues. Results about the kinetics are differing and seem to depend on the tissue,
investigated [116].
Although TH is normally heavily regulated to control DA synthesis and AADC is not the rate limiting
enzyme, AADC plays the key role in DA synthesis [125] if DOPA is administered as a drug to PD
patients. In this case DOPA crosses the blood brain barrier via L-type amino acid transporters [126]
to enter the endothelial cells from where it is sequestered to the neurons. Degradation of cytosolic
DA by MAO and COMT as well as sequestration into vesicles via VMAT2 is even more important.
Increased levels of DOPA not only have the potential to induce oxidative stress, but are also associated
with schizophrenia [127]. In addition to DOPA administration, there are already ongoing clinical studies
where AADC is targeted for gene therapy. More detailed research on human AADC would be beneficial
to understand DA metabolism, also in respect of PD.
Dopamine degradation
Upon excitation of DAergic neurons, the synaptic vesicles are emptied into the synaptic cleft (de-
granulation) to interact with the postsynaptic DA receptors or regulatory presynaptic DA autorecep-
tors [128,129]. To stop signaling, extracellular DA has to be removed from the synaptic cleft. It can
either be recycled after reuptake by DAergic neurons or be degraded after uptake by glial cells.
Neuronal reuptake by DAT [130] is followed by sequestration into the synaptic storage vesicles by
VMAT2. DA still accumulating in the cytosol, as a consequence of leakage from synaptic vesicles, is
degraded by monoamine oxidase. Oxidative deamination by MAO produces hydrogen peroxide and the
reactive 3,4-dihydroxyphenylacetaldehyde (DOPAL). This aldehyde can be inactivated by either reduc-
tion to the corresponding alcohol 3,4-dihydroxyphenylethanol (DOPET) or by further oxidation to the
carboxylic acid 3,4-dihydroxyphenylacetic acid (DOPAC) by alcohol dehydrogenase (ADH) or alde-
hyde dehydrogenase (ALDH) respectively. Under normal conditions DOPAL is predominately oxidized
to the corresponding carboxylic acid. While the reduction of DOPAL to DOPET occurs only to a very
low extent, the deamination products of NE and E are mainly reduced to the alcohol [131].
Synaptic cleft DA is also taken up by surrounding glial cells. These cells readily degrade DA by
MAO and also by catechol-O methyl transferase (COMT). COMT transfers methyl groups from S-
adenosylmethionine (SAM) to hydroxyl groups of various catecholic compounds [132,133].
3-O-methylation of DOPAC by COMT leads to homovanilic acid (HVA), one of the main degradation
products of DA. COMT operates in glial cells but there is no COMT activity in DAergic nigro-striatal
neurons [134].
Conjugation — Glucuronides and sulfates
DA and its metabolites can further undergo phase II conjugation reactions before excretion. O-Sulfatation
and O-glucuronidation occur in both CNS and periphery [135-137].
Sulfate formation is catalyzed by phenolsulfotransferases (PSTs) that transfer sulfate from
3’-phosphoadenosine-5’-phosphosulfate (PAPS) to phenolic hydroxyls. Both 3- and 4-sulfates occur,
but the 3-sulfates are predominant [132] (Figure 2). There are big differences in the extent of sulfatation
between different species [29]. In rats and especially dogs, but not in guinea pigs, there was substantial
sulfatation observed after oral DA application which did not occur after intravenous application [138].
There are even differences in respect to different brain areas with higher degree of sulfatation in the
hypothalamus and hippocampus, and a lower percentage in the striatum [136].
Glucuronidation is performed by ER-bound uridine diphosphoglucuronosyltransferases (UGTs) [139]
transferring glucuronic acid from UDP-glucuronic acid to DA. DA-4-O-glucuronide and
DA-3-O-glucuronide are formed in almost equal amounts, but no N-glucuronide was found (Figure 2).
Of all the human UGTs, only UGT1A10 was found to have substantial affinity to DA [140], but there
is no UGT1A10 expression in the brain [140] that could be responsible for the DA-glucuronides found
there [135].
The main excretion products of DA found in human urine are HVA, DOPAC, their sulfates and glu-
curonides as well as DA conjugates [132,141]. In the brain DA-Conjugates seem to play only minor
roles as in rat brain microdialysates DOPAC and HVA are the main metabolites by far [135]. There
are varying reports concerning the ratio of conjugated metabolites to non-conjugated ones and ratio of
sulfatation to glucuronidation of DA metabolites is not the same for all metabolites. For instance for DA
glucuronidation predominates over sulfatation in mouse and rat brains [135], whereas DOPAC is mainly
sulfated in human and rat brains [141].
Monoamine oxidase
MAO is a key player in monoamine degradation and target of many therapeutic inhibitors (MAOI). It
catalyzes the oxidative deamination of CAs to the corresponding aldehydes using flavin adenine dinu-
cleotide (FAD) as a cofactor and generates hydrogen peroxide as a side product. There are two forms:
MAO-A and MAO-B, which are coded by two separate genes [142,143]. The enzymes are localized in
the outer mitochondrial membrane and are found in both the CNS and the periphery. In the CNS MAO
is present in neurons, microglia cells and astrocytes. Substantia nigral neurons show comparatively low
MAO presence compared other neurons or glial cells [144].
There are species specific differences in affinity of the two enzymes: although the in vitro affinity of
both MAO types is the same, DA is mostly oxidized by MAO-B in human, but by MAO-A in rats [89].
However, MPTP, a synthetic compound causing PD-like symptoms [145] is oxidized by MAO-B in both
rat and primates [146].
Catechol-O-methyltransferase (COMT)
The Mg2+-dependent COMT transfers activated methyl groups from SAM to catechol hydroxyl groups
[132,133] (Figure 2). There are two isoforms of COMT coded by one single gene [147]. The soluble
cytoplasmic form is present in glial cells and the periphery, but the rough ER-bound isoform M-COMT
on the rough ER is prevalent in neurons. The latter one has a higher CA affinity and is mainly responsible
for metabolism of CAs originating from DAergic and NEergic neurotransmission whereas the soluble S-
COMT is more responsible for exogenous CAs [89]. COMT activity is highest in excretory organs such
as liver and kidney, but is also present in the CNS where it is most abundant in microglia cells. COMT
is less prevalent in neurons and astrocytes and was not at all detected in human DAergic nigro-striatal
neurons [134].
Metabolic differences
Metabolic differences between species, organs and tissues make elucidation of DA metabolism more
complicated; the multitude of different models used make it hard to combine the different findings
[88,131,132,138]. As an example, urinary metabolite measurements were sometimes used, making it
hard to unravel neuronal DA metabolism as these samples contain a mixture of DA metabolites derived
from all the different tissues with their different predominant metabolic reactions. In this context, it
is also important to keep in mind that almost half of the DA found in the body is synthesized in the
gastrointestinal tract [29].
Catecholamines, oxidative stress and inflammation
Dopamine oxidation and oxidative stress
As described in the previous section, oxidative deamination of CAs by MAO generates hydrogen per-
oxide causing oxidative stress in CAergic neurons or CA-degrading cells. Besides this side-chain ox-
idation, DA as well as all other CAs are prone to oxidation at their electron-rich catechol moiety. DA
and DOPA are easily oxidized enzymatically, by metal-catalysis (Fe3+) [148] or even spontaneously,
yielding the highly reactive electron-poor ortho-quinones DOPA-quinone and DA-quinone (Figure 5).
CAs can be enzymatically oxidized by cyclooxygenases (COX, prostaglandin H synthase), tyrosinase
and other enzymes [149,150]. With oxygen as the electron acceptor these reactions generate superoxide
radical anions (O 2 ). Both, quinones and ROS can react unspecifically with many cellular components
altering their functionality and thus being potentially neurodegenerative. The DOPA-Q and DA-Q read-
ily react with nucleophiles intra- and intermolecularly.
Figure 5 CA oxidation products. Catecholic compounds can be enzymatically or non-enzymatically
oxidized to their corresponding quinones. These highly reactive compounds can undergo a multitude
of different reactions, only a few are depicted here. Intramolecular cyclization and further oxidation of
DOPA- and dopaminequinone lead to the precursors of neuromelanin. DA-quinone can react with hydro-
gen peroxide to 6-hydroxydopaminequinone, or with aldehydes to tetrahydroisoquinoline like salsolinol,
both neurotoxic compounds. Cysteinylresidues of proteins or peptides readily react with DA-quinone to
form 5-cysteinyl-DA-derivatives.
CA-quinones are central oxidation intermediates leading to a multitude of different products (Figure 5).
Their amino group can attack the electrophilic quinone ring to form the cyclic aminochrome that tau-
tomerizes to 5,6-dihydroxyindole a precursor for the neuronal pigment neuromelanin [151] (Figure 5).
In the presence of iron DA-quinone can react further on to form the neurotoxin 6-hydroxydopamine
[152]. DA-quinones are also precursors for the enzymatic formation of tetrahydroisoquinolines like sal-
solinol [151,153]. Salsolinol is an endogenous neurotoxin causing oxidative stress and mitochondrial
damage by inhibition of the electron transport chain [153,154]. Additionally, salsolinol can heavily
disturb CA metabolism by inhibition of TH, DA--hydroxylase, COMT and MAO [151].
Reaction of CA-quinones with e.g. thiol groups of amino acids and proteins lead to a variety of 5-
cysteinyl-catechol derivatives. As cysteinyl residues of proteins are usually important for secondary
structure and posttranslational modifications, their derivatization leads to impaired protein function.
DAT and TH where already shown to be affected by DA-caused stress [73,155]. Conjugation of DA-
quinone with glutathione limits the cell’s capability to deal with oxidative stress.
Another protein affected by DA oxidation products is -synuclein, a major component of Lewy bodies,
which are cytosolic inclusion bodies associated with PD [156,157]. -Synuclein is a small protein
ubiquitously present in the brain [158] and a negative regulator of DA biosynthesis due to interaction
with TH [85]. DA or its derivatives as well as iron stabilize -synuclein protofibrils thus preventing
its inhibitory effect on DA synthesis, possibly leading to more oxidative stress [85]. More importantly,
with PD-associated mutations of -synuclein, these protofibrils seem to form membrane-permeabilizing
pores probably leading to severe cellular dysfunction [159]. The mode of DA action is not clear here.
As -synuclein does not contain any cysteine residues, no cysteinyl derivatization can explain this effect
[160].
The oxidation of the catechol moiety of CAs can be prevented by derivatization of its hydroxyl groups.
O-Methylation by COMT not only inhibits oxidation of the compound itself, but additionally shows
antioxidative effects by inhibition of metal-catalyzed ROS generation [161,162].
Oxidation chemistry of CAs and physiological implications have been thoroughly reviewed elsewhere
[149-151,163].
Neuromelanin
NM is a complex pigment found in specific brain regions, mostly in the substantia nigra and the locus
coerulus. NM is built of DA-derivatives and contains 15% covalently bound amino acids and 20%
adsorbed lipids [164]. It is not totally clear if enzyme-catalysis is needed in NM formation but at least
iron is required, either as cofactor or alone [148]. Altough its structure is not totally clear, NM seems to
be similar to the skin pigment melanin [165]. Studies on a synthetic DA-derived melanin suggests that
it is not a covalently bound polymer but is kept together by -stacking interactions [166].
NM is synthesized from non-vesicular DA. This could be demonstrated inhibition if its formation by
VMAT2 overexpression [148]. NM is found in lysosome-like double membrane autophagic organelles
within the cytoplasm [167], but no extracellular NM accumulation could be detected [150]. It is not
clear at which stage DA, NM or the intermediates enter these NM granules. Overexpressed VMAT1
was reported to localize in endosomes of CHO cells [168] and could explain DA accumulation as NM
precursor in endosomes or lysosomes. Additionally, with its lower affinity to DA compared to VMAT2
[35], VMAT1 could form a good secondary sink for excessive cytosolic DA. However, no VMAT1 could
be found in NM granules [167] or in neuronal cells in general [169].
It is not totally clear if the polymer is degradable in vivo or not. At least there is no enzymatic degradation
pathway known for NM, but it is sensitive to peroxidation in vitro [170]. As its formation is probably
irreversible, excessive DA is sequestered effectively, reducing oxidative stress in the cytosol rendering
NM synthesis neuroprotective [148].
Besides acting as a DA sink NM can bind transition metals, especially iron, preventing Fenton-type
OH radical generation (Fe(II) + H2O2 ! Fe(III) + OH + OH ) and protect the cell from oxidative
stress [171]. This is even more important for DAergic cells, as there is a higher ROS occurrence as
compared to other cells.
Yet NM can turn detrimental depending e.g. on the iron load [172]. At some point the accumulation of
metal ions within the polymer might become too high and turn detrimental. Oxidative stress might lead
to NM degradation through peroxidation possibly leading to an release of previously captured metal ions
or toxins, worsening the situation [173]. Neuronal cell death and subsequent release of NMmight start a
vicious circle of microglia activation and inflammation [174] causing more ROS stress and killing even
more exhausted neurons [171].
Oxidative stress, inflammation and neurodegeneration
Neuroinflammation in respect to PD is broad enough for its own review. Therefore, we refer to other
reviews that nicely summarize this topic [175-178]. Here we will present some food for thought to
illustrate the complexity of DA metabolism and its consequences.
As mentioned before, oxidative stress is part of DA metabolism due to its underlying chemistry. In
general, oxidative stress is associated with many neuronal disorders such as Alzheimer’s Disease, PD
and Schizophrenia [179]. On the other hand, ROS can be quenched by low-molecular antioxidants
and antioxidant enzymes like superoxide dismutase (SOD), glutathione peroxidases (GPX) and catalase
[180]. However, in the substantia nigra of PD patients, glutathione levels as well as the activities of
SOD, catalase, and GPX have been shown to be decreased [151], rendering the cells more vulnerable
to oxidative stress. Due to ROS overload, injurious effects such as lipid oxidation, uncoupling of the
electron transport chain or DNA damage occur, which finally leads to cell death [181-184].
Oxidative stress signals and chemoattractants released by DAergic neurons result in activation of mi-
croglia cells and subsequent inflammatory reactions [176,185-188]. First observations for microglial
activation in PD have been published in 1988 by McGeer et al. who analyzed tissue of the substantia
nigra of PD patients post mortem [185]. Exposure to environmental toxins such as rotenone, MPTP and
LPS lead to microglial activation [177]. Even years after MPTP exposure, activated microglia could
still be detected [189,190]. Activation of microglial cells can also occur because of released NM from
degenerating neurons as shown in vitro [174].
Reactive nitrogen species (NOS) and regulation of DA levels
Upon microglial activation, intracellular NO production, synthesis of cytokins, inflammatory glycopro-
teins, chemokins and cell adhesion molecules are induced, resulting in adhesion of microglia cells to
neurons. Chemoattractants released by degrading neurons promote these processes. Finally, microglia
cells become phagocytic upon DAergic neurons [176]. NO can diffuse from activated microglia cells
into DAergic neurons where it can react with superoxideanions (e.g. originating from the mitochondria)
to peroxynitrite (NO 3 ), a very potent oxidizing agent. In addition, production of hydrogen peroxide is
increased, which further increases the level of ROS in neurons [177,191].
On the other hand, peroxynitrite can generate tyrosine nitrations in proteins, inhibiting TH activity
[72,192]. NO-mediated repression of TH activity via S-thiolation on cysteine residues has also been
reported [73,74] and is discussed in [43].
An additional regulatory mechanism to control intracellular ROS levels by adapting TH activity in de-
pendence on the redox potential, is mediated by DJ-1, both on transcriptional and post-transcriptional
level. DJ-1 upregulates TH transcription by altering the acetylation state of the TH promoter. DJ-1
silencing results in lowered TH expression and most probably less DA production [193]. Interestingly,
the oxidation state of DJ-1 regulates its own activity and subsequently also TH expression [43]. Inde-
pendent of the detailed molecular regulations that take place on TH, such modification could be a sensor
for the intracellular redox level. When intracellular DA level rises, the level of oxidative stress and
simultaneously peroxynitrite formation increases. Inhibition of TH would then inhibit DA formation to
limit further ROS production. However, in the light of progressive PD such a repression of TH would
be disadvantageous, because DA production will be further limited.
Available cell models for research
Different cell lines are in use for research, related to the DAergic system. However, as described before
there are strong species and tissue specific differences in regulating DA metabolism and DA synthesis.
These differences make cell models of non-human or non-neuronal derivation not optimally suited for
PD-related research.
PC12 cells [194] have been of great benefit in elucidating the kinetics of TH and its underlying biochem-
istry. However, PC12 cells are phaeochromacytoma cells of rat adrenal medulla, thus not originating
from the CNS. In the original publication they are titled as “noradrenergic cells” [194]. Moreover, al-
though they can be differentiated into non-dividing cells, they are still of cancerogeneous nature, and
therefore, harbour a physiology far different from that of normal cells in tissue [195]. Another cell line
in use is the MN9D line. This cell line originates from mice and was generated from a fusion of embry-
onic ventral mesencephalic and neuroblastoma cells. Differentiated MN9D cells were shown to express
TH, voltage-activated sodium channels and to synthesize, harbour and release DA [196]. Although these
cells can somehow mimic a DAergic neuron like phenotype, Rick and colleagues came to the conclusion
that this cell line is not optimally suited as an in vitro model to study PD, because they do not mimic
the electrophysiological properties of DA neurons [197]. If the cells are not electrical excitible, cell to
cell communication may be lacking. Moreover, these cells are, as well as the PC12 cells, of non human
origin.
SH-SY5Y is most probably one of the most frequently used cell line to mimic DAergic neurons. This
line was subcloned from the original clone SK-N-SH, which was isolated from a neuroblastoma bone
marrow biopsy [198-200]. Besides the fact that these cells are hard to cultivate and to differentiate into
DAergic cells, these cells again originate from cancerogenous tissue. Most importantly there are reports
that state that TH and AADC could not be detected in this cell line [160,201]. Xie et al. summarized in
his review that “the SH-SY5Y cell line is not an ideal PD cell model” [201]. Balasooriya andWimalsena
characterised these cells physiologically and came to the conclusion that they are rather noradrenergic
than DAergic [202].
LUHMES (LUnd Human MESencephalic) cells may be the most promising cell model currently avail-
able. They originate from 8-week-old fetal human ventral mesencephalic tissue, conditionally immor-
talized by introduction of v-myc [203,204]. These cells are human derived, of non cancerogenous origin
and can be differentiated into postmitotic neurons, showing DAergic features, based on morphology, the
expression of neuronal and DA specific marker genes, as well as neuron type like electrophysiological
properties [204].
In moving towards personalized medicine, the future seems to lie in the use of induced pluripotent
stem cells (iPS cells) [195]. In terms of a human-based model, the use of iPS cells differentiated into
DAergic neurons is at the moment probably the most promising tool and is constantly under development
[205-208]. Regarding embryonic stem cells (ESC), Cho and colleagues developed an efficient method
to generate DAergic neurons from human ESC [209,210]. Their protocol yields in over 80 positive
functional TH positive neurons. Transplantation of these cells into a parkinsonian rat model could
demonstrate behavioral recovery [210]. However, ESC harbour the problem of availability and ethical
problems, which in turn favours the use of iPS cells.
Compared to animal models, never changing arguments put the in vitro models into critizism. Cell
models are monocultures: isolated, two-dimensional tissues, lacking a three-dimensional cell to cell
communication as well as impulses from different cell types such as astrocytes or microglia. This makes
other signals e.g. neurotransmitters like serotonin or GABA or signaling molecules like NO, missing in
these cell models. Towards this end, attempts to mimic three dimensional like tissue structures [211] as
well as co-cultures [212] are underway to encounter the proposed drawbacks and to develop models that
are closer to in vivo reality.
From the lab to clinical application
There is still no cure for PD and diagnosis is also not always easy. Different imaging methods are
available and can be used for the classification of different idiopathic PD forms [213,214].
Treatments are available to alleviate the symptoms. As a medication, DOPA in combination with a
peripherally-acting AADC inhibtor (carbidopa) is still the gold standard. Supplying DOPA as a DA
precursor circumvents TH-deficiency but has major drawbacks. High DOPA dosages might become
problematic in the light of highly toxic oxidation products which cause cell damage and inhibiting DAT
and TH [73,155]. Moreover, high DOPA dosages could also be shown to reduce AADC activity over
time and that DOPA “holidays” increased AADC activity [115,215]. Excessively supplied DOPA and its
derivatives also cause problems when they undergo degradation byMAO and COMT.MAO-caused ROS
use up the cell’s glutathione pool and can in turn cause oxidative damage. COMT-catalysed methylation
of catechols potentially exhaust the cell’s methylation capacity [216]. This reaction depends on the uni-
versal methylation cofactor SAM, which is regenerated from homocysteine by cobalamine-dependent
methylation from 5-methyltetrahydrofolate. DOPA administration was shown to lead to increased ho-
mocysteine levels and peripheral neuropathies [217-220], but this might be countered by coapplication
of COMT inhibitors or folate and cobalamine [221]. Excessive DOPA treatment should therefore be
carefully considered. Current techniques in drug delivery are moving towards extended drug release
and non-oral administration which could help to circumvent fluctuating plasma levels as generated by
current formulations [222].
Besides carbidopa and levodopa there are also drugs on the market or applied in clinical studies that
target MAO B and COMT. Other trials target specifically the motor symptoms of PD by modulating
glutamatergic, serotonergic or adrenergic systems. Different serotonin agonists for the treatment of PD
symptoms are currently in clinical and preclinical trial [222]. Deep brain stimulation is currently used
as an additional treatment option and shows amazing effects in diminishing the motor symptoms. The
disadvantage of all therapies is the fact that symptoms are only attenuated for a limited amount of time.
Another promising idea is the use of iPS cells differentiated to DAergic neurons to replace the lost
ones. These cells contain an identical genomic background as the patient but the risk of uncontrolled
proliferation is currently not completely under control. However, attempts are on the way to attenuate
these problems [223,224]. Alternative approaches aim to counter high levels of oxidative stress by
using neuroprotective agents [225] or by using antiinflammatory drugs [191]. In this respect, nicotinic
receptors are also promising targets for therapy. There exist reports showing that smoking leads to
lowered DOPA dosages in PD patients. Furthermore, stimulation with a nicotinic agonist have resulted
in increased amounts of TH protein [226-228].
A more recent wave of clinical phase I and II trials uses adeno-associated virus systems to deliver
the important enzymes of DA metabolism - AADC, TH and GTPCH - into the affected brain region.
However, by delivering AADC to the system [229,230], the treatment is only symptomatic, rather than
targeting the roots of the disease. Engineering TH and GTPCH instead of AADC alone could help to
improve the endogenous DA system. Such an attempt has already been made in vitro [231], in animal
models [232] and is now also part of a phase I study [233]. An alternative gene therapy approach could
be the use of engineered and more active TH versions, providing increased tyrosine hydroxylation rates
and higher stability towards oxidative stress. However, this might be ethically more complicated and
unwanted side effects must be minimized. For further details in state-of-the-art therapeutics and ongoing
developments we recommend the article of Poewe et al. [222].
Conclusions
The metabolism of DA sets DAergic neurons under constant oxidative stress. Therefore, DA homeosta-
sis and ROS detoxification is of special importance. Synthesis and regulation of DA has been heavily
investigated in the 20th century and many of its metabolic products as well as regulation of the synthesis
enzymes, have been unraveled in in vitro and in vivo experiments.
However, a detailed analysis of the DA metabolism and its consequences to the cellular integrity is
important to understand disease mechanisms. It is especially important to distinguish between animal
models and human based data. To investigate DA metabolism and degeneration of DAergic neurons
as observed in PD, a human cell culture model harbouring the full metabolic pathway is indispensable.
Although animal models have the advantage of having the whole organism with all the different tissues
available, there are strong species specific differences in DA metabolism and regulation. For this reason,
we feel that models of non-human and non-neuronal origin are only of limited use for research on human
neurodegenerative diseases.
As presented here for DA metabolism and associated processes, there are intricate regulatory mech-
anisms in place for many biological pathways. To fully understand them, it is important to not only
look at single aspects but to combine the different omics technologies with more classical fields of cell
biology, enzymology and neuroanatomy to obtain a comprehensive systems level view.
In the case of PD, insights into DA metabolism, ROS detoxification as well as the consequences of
DA-derived ROS-overload will help to understand the underlying problems of the disease and thus to
develop new approaches to tackle this human burden.
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